Zacks Research Issues Optimistic Forecast for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Monday, February 3rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $2.02 for the year, up from their prior estimate of $1.78. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Several other analysts also recently weighed in on SRPT. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. HC Wainwright reissued a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, January 30th. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Robert W. Baird lowered their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Up 0.2 %

Shares of NASDAQ:SRPT opened at $114.08 on Wednesday. The company has a market cap of $10.90 billion, a PE ratio of 91.26 and a beta of 0.75. The company’s 50-day moving average price is $122.45 and its 200 day moving average price is $126.50. Sarepta Therapeutics has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently made changes to their positions in the stock. CIBC Asset Management Inc boosted its holdings in shares of Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. Louisiana State Employees Retirement System lifted its stake in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after acquiring an additional 100 shares during the last quarter. Manchester Capital Management LLC lifted its stake in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 138 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its stake in Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.